Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026
Neurocrine presented two-year data from the Phase 3 CAHtalyst Adult study at ENDO 2026, showing sustained improvements in cardiometabolic outcomes for patients with classic congenital adrenal hyperplasia. Among overweight or obese participants, 37% achieved clinically meaningful weight loss (>5%), and 43% of those with baseline insulin resistance were no longer insulin resistant after two years of treatment.
Key figures
- Drug Name
- CRENESSITY (crinecerfont)
- Phase Of Trial
- Phase 3
- Study name
- CAHtalyst Adult
- Patient count
- 182
- Weight loss gt 5pct
- 37%
- Gc dose reduction pct
- 38%
- Patient satisfaction pct
- 96%
- Insulin resistance resolved
- 43%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.